Latest Pharma Insights
Samsung Biologics Strike Threat Puts Client Confidence In Focus
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Biobeat Says Chest Patch Could Provide Alternative To Cuff-Based BP Monitoring
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Samsung Biologics Strike Threat Puts Client Confidence In Focus
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Biobeat Says Chest Patch Could Provide Alternative To Cuff-Based BP Monitoring
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Beiersdorf: Nivea Turnaround ‘Progressing’ Despite 4.9% Organic Sales Drop
Beiersdorf continues tailoring Nivea’s innovation strategy to local market trends as the brand’s third-quarter organic sales fell 4.9%, while its Derma business growth accelerates.
HBW Insight - October 27, 2026
Beiersdorf continues tailoring Nivea’s innovation strategy to local market trends as the brand’s third-quarter organic sales fell 4.9%, while its Derma business growth accelerates.
HBW Insight - October 27, 2026
US FDA Plans Pilot Program For OTC Switches, Other Nonprescription Drugs
FDA soon will launch pilot giving OTC drug sponsors early, structured talks with agency, which should help efforts to encourage more Rx-to-OTC switches.
HBW Insight - October 27, 2026
FDA soon will launch pilot giving OTC drug sponsors early, structured talks with agency, which should help efforts to encourage more Rx-to-OTC switches.
HBW Insight - October 27, 2026
People On The Move: Appointments At Haleon, Sanotact, IADSA
A round-up of the latest moves in Europe's consumer health sector: Haleon appoints general manager for the Nordics; Sanotact names director for Germany; chair of the IADSA Company Council elected.
HBW Insight - October 27, 2026
A round-up of the latest moves in Europe's consumer health sector: Haleon appoints general manager for the Nordics; Sanotact names director for Germany; chair of the IADSA Company Council elected.
HBW Insight - October 27, 2026
US Industry Again Asking Why A Federal Agency Won’t Keep Separate Dietary Supplements Office?
Supplement industry groups oppose National Institutes of Health’s proposal to move Office of Dietary Supplements to be part of the Office of Nutrition Research, which would be moved to the Division of Program Coordination, Planning, and Strategic Initiatives.
HBW Insight - October 27, 2026
Supplement industry groups oppose National Institutes of Health’s proposal to move Office of Dietary Supplements to be part of the Office of Nutrition Research, which would be moved to the Division of Program Coordination, Planning, and Strategic Initiatives.
HBW Insight - October 27, 2026
Beauty Marketers Risk Consumer Backlash, Regulatory Scrutiny When AI Overpromises In Ads – NAD
Brands that use AI to polish product performance visuals or that include synthetic figures in ads risk turning off shoppers and drawing regulatory or legal scrutiny if the visuals oversell what a product can do, says the National Advertising Division.
HBW Insight - October 27, 2026
Brands that use AI to polish product performance visuals or that include synthetic figures in ads risk turning off shoppers and drawing regulatory or legal scrutiny if the visuals oversell what a product can do, says the National Advertising Division.
HBW Insight - October 27, 2026
Teva Seals Trump Administration API Deal With MFN Pricing Pledge
Teva joins US efforts to strengthen the domestic supply chain, as it finalizes a governmental deal to donate API for key products, as well as pricing commitments for Medicaid and MFN policies for applicable future innovative launches.
Generics Bulletin - October 27, 2026
Teva joins US efforts to strengthen the domestic supply chain, as it finalizes a governmental deal to donate API for key products, as well as pricing commitments for Medicaid and MFN policies for applicable future innovative launches.
Generics Bulletin - October 27, 2026
Cosette Pharmaceuticals Gets FDA Nod For Liquid Oral Formulation Of Evoxac
As eight generic companies continue to compete for market share of Evoxac capsules, Cosette is now listed in the Orange Book as the only approved provider of a liquid oral formulation, following approval through the 505(b)(2) pathway.
Generics Bulletin - October 27, 2026
As eight generic companies continue to compete for market share of Evoxac capsules, Cosette is now listed in the Orange Book as the only approved provider of a liquid oral formulation, following approval through the 505(b)(2) pathway.
Generics Bulletin - October 27, 2026
Who’s Hired? Lupin Lifts Legal Leader From Teva
Lupin has looked to Teva to recruit its new chief legal officer. Meanwhile, Fresenius Kabi has a new biopharma business development lead; Centrient has named a new CFO; and Pharmanovia has appointed a new head of medical affairs.
Generics Bulletin - October 27, 2026
Lupin has looked to Teva to recruit its new chief legal officer. Meanwhile, Fresenius Kabi has a new biopharma business development lead; Centrient has named a new CFO; and Pharmanovia has appointed a new head of medical affairs.
Generics Bulletin - October 27, 2026
Is It Time To Phase Out ‘Women’s Health’?
‘Women’s health’ offers a distinct medical term for half the global population, but is it causing more harm than good? Some industry spectators believe the label has a shelf life.
In Vivo - October 27, 2026
‘Women’s health’ offers a distinct medical term for half the global population, but is it causing more harm than good? Some industry spectators believe the label has a shelf life.
In Vivo - October 27, 2026
Brainomix’s AI-Powered Precision Medicine Stroke Offering Targets Non-Specialist Centers
AI technology can directly address the unmet need whereby most sufferers of a stroke are not taken to a central stroke treatment hub but to a spoke site for their initial care. Brainomix CMO George Harston explained the problem and the solution at the annual CPI meeting in London in October.
In Vivo - October 27, 2026
AI technology can directly address the unmet need whereby most sufferers of a stroke are not taken to a central stroke treatment hub but to a spoke site for their initial care. Brainomix CMO George Harston explained the problem and the solution at the annual CPI meeting in London in October.
In Vivo - October 27, 2026
Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans
In this episode of Strategic Intent, David Evans, Partner at Sofinnova Partners, discusses his transition from Roche Venture Fund, different investment strategies, provides a general market analysis across Europe and US, and looks at growing therapeutic area trends within biotech.
In Vivo - October 27, 2026
In this episode of Strategic Intent, David Evans, Partner at Sofinnova Partners, discusses his transition from Roche Venture Fund, different investment strategies, provides a general market analysis across Europe and US, and looks at growing therapeutic area trends within biotech.
In Vivo - October 27, 2026